Literature DB >> 14431638

The properdin system and immunity. XII. Assay, properties and partial purification of a hydrazine-sensitive serum factor (factor A) in the properdin system.

J PENSKY, L WURZ, L PILLEMER, I H LEPOW.   

Abstract

Keywords:  PROPERDIN/chemistry

Mesh:

Substances:

Year:  1959        PMID: 14431638

Source DB:  PubMed          Journal:  Z Immun exp ther        ISSN: 0372-9052


× No keyword cloud information.
  8 in total

1.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

2.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

Review 3.  Properdin: approaching four decades of research.

Authors:  K K Maves; J M Weiler
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors.

Authors:  D R Schultz; K D Miller
Journal:  Infect Immun       Date:  1974-07       Impact factor: 3.441

5.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

Authors:  P R Craddock; J Fehr; A P Dalmasso; K L Brighan; H S Jacob
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

6.  The role of properdin in the alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

7.  Genetic polymorphism in human glycine-rich beta-glycoprotein.

Authors:  C A Alper; T Boenisch; L Watson
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

8.  The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.

Authors:  C A Alper; I Goodkofsky; I H Lepow
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.